Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Hosszuheteny – page 11

538 clinical trials in Hosszuheteny, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Hosszuheteny at a glance
538
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

538 trials in Hosszuheteny

Open in trial search

Study of Pozelimab and Cemdisiran for Adults with Geographic Atrophy from Age-Related Macular Degeneration

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study on the Effectiveness and Safety of Ianalumab for Patients with Diffuse Cutaneous Systemic Sclerosis

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Study Comparing Amivantamab and Chemotherapy Versus Cetuximab and Chemotherapy for Patients with Advanced Colorectal Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen - Cilag International

Study on Pegaspargase and Rituximab for Treating Children with Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Pegaspargase
  • Sponsor:Semmelweis University

Study on Frexalimab, SAR442970, and Rilzabrutinib for Patients Aged 16-75 with Focal Segmental Glomerulosclerosis or Minimal Change Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on the Safety and Effectiveness of HDP-101 for Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:HDP-101
  • Sponsor:Heidelberg Pharma AG

Neoplasm malignant+1

Recruiting

Study on the Safety of Encorafenib, Binimetinib, and Ribociclib for Patients with Solid Tumors

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Pfizer Inc.

Study of Lisaftoclax Alone or with Drug Combination for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Ascentage Pharma Group Inc.

Myelofibrosis

Recruiting

Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Navtemadlin
  • Sponsor:Kartos Therapeutics Inc.

Study of Pembrolizumab and V940 for Treating Non-Small Cell Lung Cancer in Patients with Resectable Stage II to IIIB (N2) Not Achieving Complete Response

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study on Long-term Safety of JNJ-81201887 for Patients with Geographic Atrophy Due to Age-related Macular Degeneration

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Onzemipgene parvec
  • Sponsor:Janssen - Cilag International

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:Institut Gustave Roussy

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Hosszuheteny

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking clinical trials focusing on atherosclerotic cardiovascular disease prevention are currently underway. These studies aim to evaluate innovative therapeutic approaches for reducing major adverse cardiovascular events in high-risk patients.

  • Primary Prevention Studies
  • Cardiovascular Risk Management
  • Novel Therapeutic Interventions

The research specifically targets patients requiring preventive care for ASCVD, investigating treatments that could significantly impact cardiovascular mortality and morbidity rates.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.